However, in patients with unresectable tumors or those in whom causative tumors are not found, currently available treatments have had limited efficacy in healing the osteomalacia, reducing symptoms, and maintaining serum phosphate, parathyroid hormone, and alkaline phosphatase levels within the normal range;(4) thus, burosumab may satisfy the unmet need for this population. This evidence concerns the gene PTH and osteomalacia.